As of October 22, 2026, Takeda Pharmaceutical Co Ltd ADR (TAK) trades at $20.36. No model fair value is published for TAK. TAK reports its financial statements in JPY. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — TAK valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Takeda Pharmaceutical Co Ltd ADR (TAK) is next scheduled to report earnings on Oct 29, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $0.31.
Reported EPS came in above the analyst estimate in 2 of the last 6 reports. The median share-price change across a report, in either direction, was 2.8%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Jul 30, 2026 | $0.41 | $0.48 | +17.1% | -2.8% |
| May 13, 2026 | — | $-0.74 | — | +1.3% |
| Jan 29, 2026 | — | $0.21 | — | +2.9% |
| Oct 30, 2025 | $0.15 | $-0.03 | -116.8% | -3.9% |
| Jul 30, 2025 | $0.20 | $151.00 | +75174.2% | -5.0% |
| Jun 25, 2025 | $-0.17 | $-0.23 | -37.1% | -0.7% |
| Jan 30, 2025 | $0.63 | $0.05 | -92.4% | +2.9% |
| Oct 31, 2024 | $87.45 | $29.07 | -66.8% | +0.4% |
Equity Rank's fundamental strength composite scores TAK at 61.1/100 (B-, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +22.2% per year and gross margin has moved -18.1 pp. Its SAVE composite score has moved +0.9 over the past 30 days.
TAK reports its financial statements in JPY. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Takeda Pharmaceutical Co Ltd ADR (TAK) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Takeda Pharmaceutical Co Ltd ADR (TAK) is classified in the Pharmaceuticals sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Specialty & Generic Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/TAK. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.